Piscataway, NJ, June 2, 2022–Camber Pharmaceuticals is pleased to announce the addition of Oxcarbazepine Tablets to their current portfolio.
Oxcarbazepine Tablets are indicated in use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
Oxcarbazepine Tablets from Camber are available in 150, 300, and 600 mg strengths, all in 100 count bottles.
To find out more about Oxcarbazepine Tablets please visit https://www.camberpharma.com or see our launch video at https://www.camberpharma.com/oxcarbazepine/
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero, of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.
